Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) | NETWORK |
| Merck Sharp & Dohme LLC | INDUSTRY |
| Astellas Pharma Inc | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this observational study is to estimate the 90-day response rates to treatment for a first episode of C. difficile infections (CDI) in adult transplant recipients.
The primary objective of this observational study is to estimate the 90-day response rates to treatment for a first episode of C. difficile infections (CDI) in adult transplant recipients. This includes treatment success, recurrence, and complications in a prospectively followed cohort of solid organ and hematopoietic stem cell transplant patients. Patients who develop CDI within 2 years after transplantation will be enrolled and followed prospectively for 90 days after enrollment. Specimens of stool and serum collected within 48 hours of initiation of treatment will be stored locally for future epidemiologic studies to examine the immunologic and microbiologic risk factors for relapse and treatment failure, as well as complications of CDI in the transplant population. Response rates will be classified by organ type, hematopoietic stem cell transplant typ, treatment regimen, and immunosuppressive regimen.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CDI patients | Adults with a first episode of CDI within 2 years after solid-organ or stem-cell transplant. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Response to antibiotic treatment for CDI: clinical cure | The planned first course of CDI treatment was completed with resolution of symptoms or less than 3 loose stools per day for at least two consecutive days maintained until end of treatment and two days after treatment course ended. | 90 days |
| Response to antibiotic treatment for CDI: sustained clinical cure | Clinical cure achieved and maintained for 40 days post treatment initiation without recurrences, complications, ICU with CDI, or death as defined below | 90 days |
| Response to antibiotic treatment for CDI: global cure | Clinical cure achieved and maintained for 90 days post treatment initiation without recurrences, complications, including ICU with CDI, or death as defined below. | 90 days |
| Response to antibiotic treatment for CDI: relapse | A new episode of CDI after clinical cure and within 4 weeks after treatment initiation. | 90 days |
| Response to antibiotic treatment for CDI: reinfection | A new episode of CDI after clinical cure and beyond 4 weeks after treatment initiation | 90 days |
| Response to antibiotic treatment for CDI: complications | The study will collect the incidence of specific complications as assessed by the site investigator: perforation of the colon; development of toxic megacolon; need for abdominal surgery related to CDI; transfer to the ICU with CDI; death from CDI-related cause. | 90 days |
| Measure | Description | Time Frame |
|---|---|---|
| Describe patients who are successfully treatment for CDI | Patients will be described by demographics (age, race, sex), type of transplant received, specific treatment for CDI, and the strain of C. difficile with which they were infected. | 90 days |
| Describe differences in antibiotic regimens and other CDI treatments across geographic regions (US, Europe, South America) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults with a first episode of CDI within 2 years post solid-organ or stem-cell transplant.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean-Michel Molina, MD | Hôpital Saint-Louis, Service de Maladies Infectieuses | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Minnesota Medical Center | Minneapolis | Minnesota | 55455 | United States | ||
| Mayo Clinic |
Not provided
| Label | URL |
|---|---|
| INSIGHT network website, CDIFF home page | View source |
| ID | Type | URL | Comment |
|---|---|---|---|
| Study Protocol | View IPD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Copenhagen HIV Programme |
| OTHER_GOV |
| Medical Research Council | OTHER_GOV |
| Washington D.C. Veterans Affairs Medical Center | FED |
Not provided
Not provided
Not provided
serum, stool
| 90 days |
| All-cause mortality | 90 days |
| Response to treatment for CDI (as defined above) by treatment regimen | 90 days |
| Response to treatment for CDI (as defined above) by type of transplant (solid organ vs. hematopoietic/stem cell) | 90 days |
| Assay differences across sites | Describe assays used to detect C. difficile organisms and toxin in stool by site at which participants are enrolled. | 90 days |
| Rochester |
| Minnesota |
| 55905 |
| United States |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | United States |
| Hospital Italiano de Buenos Aires | Buenos Aires | C1181ACH | Argentina |
| CHIP, Department of Infectious Diseases, Section 2100 | Copenhagen | 2100 | Denmark |
| Klinik I fur Innere Medizin der Universitat zu Koln, Studienburo fur Infektiologie u. HIV | Cologne | Germany |
| Hospital Clinic de Barcelona | Barcelona | Spain |
| Hospital Universitario Doce de Octubre | Madrid | Spain |